Join to View Full Profile
4102 N Roxboro StDurham, NC 27704
Phone+1 919-595-2000
Fax+1 919-595-2190
Are you Dr. Rich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Cadmus Rich, MD is an ophthalmologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina.
Education & Training
University of North Carolina HospitalsResidency, Ophthalmology, 1997 - 2000
Carilion Clinic-Virginia Tech Carilion School of MedicineInternship, Transitional Year, 1995 - 1996
University of North Carolina at Chapel Hill School of MedicineClass of 1995
Certifications & Licensure
NC State Medical License 1996 - 2025
Publications & Presentations
PubMed
- 4 citationsTumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model.Sen Ma, Ruben V Huis In't Veld, Yang Hao, Zili Gu, Cadmus Rich
Investigative Ophthalmology & Visual Science. 2024-01-02 - 13 citationsImmune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant t...Ruben V Huis In 't Veld, Sen Ma, Rhonda C Kines, Anneli Savinainen, Cadmus Rich
Cancer Immunology, Immunotherapy. 2023-07-01 - 8 citationsIn Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity.Sen Ma, Ruben V Huis In't Veld, Alexander Houy, Marc-Henri Stern, Cadmus Rich
Investigative Ophthalmology & Visual Science. 2023-06-01
Press Mentions
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual MeetingFebruary 24th, 2020
SUBSPECIALTY NEWS: Gene Therapy Data from AAO, FDA Approval of Beovu, and MoreNovember 1st, 2019- Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA ForJanuary 4th, 2019
- Join now to see all
